Citi lowered the firm’s price target on QuidelOrtho (QDEL) to $40 from $50 and keeps a Buy rating on the shares. The firm views the company’s Q2 report and cost actions planned for the back of half of 2025 positively.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QDEL: